Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb study of ALX-0061 plus methotrexate in rheumatoid arthritis
2014-003033-26Phase 2Completed
- Sponsor
- Ablynx
- Start
- Nov 2014
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing ALX-0061 plus methotrexate with Placebo plus methotrexate (2 arms). Primary endpoint: Reduction of signs and symptoms of rheumatoid arthritis. Started Nov 2014; status: completed.
02
Drugs
vobarilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2014-003033-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003033-26.